Core Viewpoint - Profound Medical Corp. has launched a new TULSA program in collaboration with Texas Prostate and Dallas Medical Center, providing Medicare patients in Texas access to the TULSA Procedure, a minimally invasive treatment for prostate cancer and benign prostatic hyperplasia (BPH) without the need for surgery [1][2][3] Group 1: TULSA Procedure Overview - The TULSA Procedure offers effective prostate treatment with minimal side effects compared to traditional surgery, such as incontinence or erectile dysfunction [2] - The procedure is performed using the TULSA-PRO system, which combines real-time MRI guidance, AI-enhanced planning, and robotically-driven ultrasound to precisely ablate targeted prostate tissue [5] - TULSA is a single-session, incision-free procedure that allows patients to return home the same day, with no procedural blood loss and a significantly lower risk of complications [3][5] Group 2: Medicare Coverage and Accessibility - Medicare coverage for the TULSA Procedure was granted in January 2025, allowing it to be performed in various settings, including Hospital Outpatient and Ambulatory Surgical Centers [2] - The collaboration with Dallas Medical Center enables Texas Prostate to perform TULSA procedures exclusively at this facility, enhancing patient access to this advanced treatment [2][3] Group 3: Company Background and Future Potential - Profound Medical Corp. is a commercial-stage medical device company focused on developing incision-free therapies for diseased tissue ablation [4] - The TULSA Procedure has the potential to become a mainstream treatment for a wide range of prostate diseases, including low-, intermediate-, and high-risk prostate cancer, as well as BPH [5] - The TULSA-PRO system is CE marked, Health Canada approved, and 510(k) cleared by the U.S. FDA, indicating its regulatory compliance and readiness for market [5]